NewsThe Daily WireMay 1, 2026United States
Appeals Court Blocks FDA Policy on Mail-Order Abortion Pills
The U.S. Court of Appeals for the Fifth Circuit has issued a ruling blocking the FDA's 2023 policy that allowed the abortion drug mifepristone to be prescribed via telehealth and delivered by mail. The court found the regulation likely unlawful, citing concerns over safety data and the impact on state laws.
Read the full story at The Daily WireWhy It Matters
This ruling changes how patients can access abortion medication nationwide by reinstating in-person medical requirements for .
Key Facts
- The Fifth Circuit Court of Appeals blocked the FDA's 2023 rule allowing mail-order mifepristone.
- The court ruled that the FDA failed to adequately study the safety of remote dispensing.
- The decision requires a return to in-person medical visits for prescribing the drug.
- Louisiana argued the policy undermined state laws and increased Medicaid costs for emergency care.